PDCD1 and neoplasm: Some large-scale cancer genome projects, such as TCGA, which have revealed the genomic landscapes of several cancer types, can also be integrated with our network association prediction (Fig. 1c, d) to identify genetic aberrations and pathways that are associated with tumor response to anti-PD-1 therapy in a given cancer type.